UTHR - Company ID 0001082554
UNITED THERAPEUTICS Corp trades as UTHR and has a market capitalization of $23.39 B, making it the #568 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $3.18B, up 10.6% from the prior year and net income of $1.33B. This page tracks UNITED THERAPEUTICS Corp through 4,203 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-07-09
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Over the last 9 fiscal years UNITED THERAPEUTICS Corp's revenue grew from $1.60B to $3.18B, a compound annual growth rate of 7.9%. Net profit margin expanded from 28.2% to 41.9% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-22 |
| Insider trade | 4 | 2026-05-22 |
| Insider sale notice | 144 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-20 |
| Insider trade | 4 | 2026-05-19 |
| Insider trade | 4 | 2026-05-19 |
United Therapeutics Corporation Announces TETON-1 Study of Tyvaso Published in The New England Journal of Medicine and Presented at ATS 2026 – United Therapeutics Investor Relations
United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Presented at ATS 2026 – United Therapeutics Investor Relations
United Therapeutics Corporation Announces FDA Clearance to Proceed with UHeart Xenotransplantation Clinical Trial – United Therapeutics Investor Relations
United Therapeutics Corporation to Present at the RBC Capital Markets Global Healthcare Conference
United Therapeutics Corporation Presents New Data from TETON-1, ADVANCE OUTCOMES, and Additional Research in Pulmonary Hypertension and Pulmonary Fibrosis at ATS 2026
The largest companies sharing UNITED THERAPEUTICS Corp's SEC industry classification (pharmaceutical preparations).
UNITED THERAPEUTICS Corp (UTHR) has a market capitalization of $23.39 B as of 2026-07-09, ranking #568 among US-listed companies.
UNITED THERAPEUTICS Corp reported revenue of $3.18B for fiscal year 2025, an increase of 10.6% year over year.
Yes. UNITED THERAPEUTICS Corp reported net income of $1.33B in its latest fiscal year.